Epidermal growth factor receptor (EGFR), one of the important targets in the development of the anticancer compound, is a member of the ErbB receptor tyrosine kinase receptor family and is highly expressed in solid tumors. Inhibition of EGFR is important for cancer treatment to inhibit the progression and growth of EGFR‐expressing tumor cells. Agents targeting EGFR are successful drugs involved in the treatment of various cancers, particularly colorectal, head, neck, lung, and breast cancers. In this study, the design of some novel benzimidazole compounds that can interact with EGFR kinase enzyme, synthesis and analysis of these compounds, and evaluation of their biological activities in vitro was aimed. To reach the target compounds, by reacting acid hydrazides with alkyl isothiocyanates, thiosemicarbazides were formed, then cyclization of these compounds with concentrated sulfuric acid or sodium hydroxide, thiadiazole, or triazole derivatives were obtained. As a result of the study, a total of 38 new benzimidazole derivatives was obtained, and the structures of these compounds were clarified by elemental analysis, mass, 1H, and 13C NMR spectroscopy. Also, the structure of compound 4c was proven by X‐ray crystallography. Molecular docking studies of the synthesized compounds have also been carried out, some molecules with high docking scores have been selected and EGFR kinase inhibitor properties have been tested. Among the compounds tested, it was determined that the most active compound was 12a, which inhibited 68% EGFR at a concentration of 10 μM.
Background and Purpose: Carvedilol is a third-generation β-adrenoceptor antagonist, which also stimulates β-arrestins. β-arrestins initiate intracellular signalling and are involved in insulin release and sensitivity. Carvedilol is superior in effectiveness to other drugs that are used for similar indications and does not cause insulin resistance or diabetes, which can occur with other β-antagonists. We have shown that carvedilol increased glucose usage in C2C12 cells. We investigate the biased agonist efficacy of carvedilol on β-arrestins. Experimental Approach: Streptozotocin (STZ)-induced diabetes rat model was used to induce metabolic and cardiac disorders. After 8 weeks of diabetes, animals were treated with carvedilol or vehicle for another 4 weeks. In vitro heart function was evaluated at baseline as well as with increasing concentrations of isoprenaline. Effects of diabetes and carvedilol treatment on β-arrestins, ERK, PPARα, CD36 proteins and pyruvate kinase activity were evaluated. β-arrestins were silenced in C2C12 cells by using siRNA. Acute effects of carvedilol on ERK, CD36, mitochondrial transcription factor A, cardiolipin proteins and citrate synthase activity were investigated. Key Results: Carvedilol reversed the deterioration of cardiac function in diabetes and diabetes-induced decrease in β-arrestins in rats. Carvedilol decreased the expression of CD36 in diabetes and increased mitochondrial transcription factor A and cardiolipin proteins. Silencing of β-arrestins in cells prevented the effects of carvedilol on these proteins. Conclusion and Implications: The metabolic effects of carvedilol seem to be related to biased activation of β-arrestins. Patients with cardiovascular and metabolic disorders may benefit from new compounds that selectively act on β-arrestins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.